Opportunity radar
4,186,134 patents indexed · 165,974,948 citations · issued 2005-01-04 → 2026-05-05
Showing50 of 30,058
Pharma (A61K)Therapy methods (A61P)Med devices (A61M)Agriculture (A01)Hand tools (B25)Consumer (A47)Energy (H01M)AI / ML (G06N)
| Patent # | Title | Assets | Issued | Expires | Fwd cites | Score |
|---|---|---|---|---|---|---|
| 12617823 | Broad-spectrum peptide antigen of the novel coronavirus SARS-COV-2, specific neutralizing antibody and use thereof | 🖼🧊📄§ | 2026-05-05 | 2041-07-21 | 0 | 31 |
| 12617862 | Anti-CD73 antibody and application thereof | 🖼🧊📄§ | 2026-05-05 | 2040-08-20 | 0 | 31 |
| 12617846 | Subcutaneous (SC) administration of anti-C5 antibodies for treatment of complement-associated conditions | 🖼🧊📄§ | 2026-05-05 | 2041-05-06 | 0 | 31 |
| 12617857 | Chemokine receptor 4 (CXCR4) antagonist antibodies | 🖼🧊📄§ | 2026-05-05 | 2041-04-22 | 0 | 31 |
| 12617827 | Self-assembling peptide | 🖼🧊📄§ | 2026-05-05 | 2041-07-29 | 0 | 31 |
| 12616683 | Combination therapy for the treatment of gastrointestinal stromal tumors | 🖼🧊📄§ | 2026-05-05 | 2044-04-10 | 0 | 31 |
| 12616704 | Cannabichromene formulation for pain management | 🖼🧊📄§ | 2026-05-05 | 2041-03-31 | 0 | 31 |
| 12617835 | Chimeric autoantibody receptor (CAAR) that binds autoantibodies targeting the central nervous system in neurological autoimmune disease | 🖼🧊📄§ | 2026-05-05 | 2040-06-05 | 0 | 31 |
| 12616661 | Composition for type II diabetics and for use in providing sustained energy release over time | 🖼🧊📄§ | 2026-05-05 | 2039-03-07 | 0 | 31 |
| 12616755 | Antifungal quercetin conjugates, methods of preparation and uses thereof | 🖼🧊📄§ | 2026-05-05 | 2045-10-08 | 0 | 31 |
| 12616652 | Lenses for treating ocular diseases and preparation method thereof | 🖼🧊📄§ | 2026-05-05 | 2042-12-29 | 0 | 31 |
| 12616745 | Influenza virus backbone | 🖼🧊📄§ | 2026-05-05 | 2040-06-05 | 0 | 31 |
| 12616749 | Methods for treatment of psoriasis with an anti-oxLDL antibody | 🖼🧊📄§ | 2026-05-05 | 2044-06-21 | 0 | 31 |
| 12616782 | Use of mitochondria to treat and/or prevent tendon injury or its related disease | 🖼🧊📄§ | 2026-05-05 | 2041-03-19 | 0 | 31 |
| 12616721 | Stratified squamous epithelial cell normal differentiation and maturation promoting agent, epithelial disease therapeutic agent, and stratified squamous epithelial cell normal differentiation and maturation promoting method | 🖼🧊📄§ | 2026-05-05 | 2039-01-11 | 0 | 31 |
| 12616696 | Crystalline forms of (p)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2′-(2-(2-hydroxypropan-2-yl)pyrimidin-4-yl)-5′,6-dimethyl-2h-[1,4′-bipyridin]-2-one | 🖼🧊📄§ | 2026-05-05 | 2041-03-26 | 0 | 31 |
| 12616663 | Plant-derived exosome-like nanoparticles inhibit bacterial pathogenicity | 🖼🧊📄§ | 2026-05-05 | 2040-03-02 | 0 | 31 |
| 12617838 | Auto/allo-immune defense receptors for the selective targeting of activated pathogenic T cells and NK cells | 🖼🧊📄§ | 2026-05-05 | 2039-04-25 | 0 | 31 |
| 12617848 | Methods of treating ocular pathologies using bifunctional molecules that target growth factors | 🖼🧊📄§ | 2026-05-05 | 2041-11-08 | 0 | 31 |
| 12617834 | Composition of NY-ESO-1-specific t cell receptors restricted on multiple major histocompatibility complex molecules | 🖼🧊📄§ | 2026-05-05 | 2039-09-04 | 0 | 31 |
| 12617842 | Antiviral immunotherapy by membrane receptor ligation | 🖼🧊📄§ | 2026-05-05 | 2041-12-02 | 0 | 31 |
| 12617818 | Compositions and methods for modulating myosin subfragment-2 coiled coil stability and methods for using them | 🖼🧊📄§ | 2026-05-05 | 2041-03-25 | 0 | 31 |
| 12618067 | Targeted delivery of an inhibitor of miR-21 to macrophages for the treatment of pulmonary fibrosis | 🖼🧊📄§ | 2026-05-05 | 2041-04-09 | 0 | 31 |
| 12617779 | Self degradation-type CDK9 inhibitor prodrug and liposome encapsulating same | 🖼🧊📄§ | 2026-05-05 | 2042-08-22 | 0 | 31 |
| 12618840 | Antibody for detecting acetylation of COX2 protein, and uses thereof | 🖼🧊📄§ | 2026-05-05 | 2040-09-18 | 0 | 31 |
| 12618839 | Antibodies for detecting Epstein Barr virus-positive gastric cancer | 🖼🧊📄§ | 2026-05-05 | 2040-10-23 | 0 | 31 |
| 12617863 | Humanized anti-glycoprotein Ib alpha (GPIbalpha) antibodies | 🖼🧊📄§ | 2026-05-05 | 2040-12-10 | 0 | 31 |
| 12617860 | Anti-TNFR2 antibody and uses thereof | 🖼🧊📄§ | 2026-05-05 | 2041-01-05 | 0 | 31 |
| 12617868 | Activation of (Na++K+)-ATPase inhibits platelet aggregation and prevents thrombosis | 🖼🧊📄§ | 2026-05-05 | 2042-11-08 | 0 | 31 |
| 12617799 | Pyrazolopyrimidinone compounds | 🖼🧊📄§ | 2026-05-05 | 2042-03-25 | 0 | 31 |
| 12620468 | Personalized liver cancer treatment | 🖼🧊📄§ | 2026-05-05 | 2045-03-06 | 0 | 31 |
| 12616742 | Recombinant heme oxygenase-1 (HO-1) for the treatment of sickle cell disease | 🖼🧊📄§ | 2026-05-05 | 2040-07-24 | 0 | 31 |
| 12617769 | Chemical compound as thyroid hormone beta receptor agonist and use thereof | 🖼🧊📄§ | 2026-05-05 | 2040-09-23 | 0 | 31 |
| 12617755 | Compositions and methods for treating metabolic disease | 🖼🧊📄§ | 2026-05-05 | 2040-08-03 | 0 | 31 |
| 12616672 | Methods for assessing risk of cardiovascular disease and methods and compounds for use in treating or preventing cardiovascular disease | 🖼🧊📄§ | 2026-05-05 | 2038-09-19 | 0 | 31 |
| 12616680 | Combined use of biotin and thiamine in the treatment of huntington's disease | 🖼🧊📄§ | 2026-05-05 | 2040-09-23 | 0 | 31 |
| 12616688 | Cell glycocalyx protection effect of anisodamine | 🖼🧊📄§ | 2026-05-05 | 2041-09-01 | 0 | 31 |
| 12616695 | Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of rare chronic inflammatory pulmonary diseases | 🖼🧊📄§ | 2026-05-05 | 2041-01-29 | 0 | 31 |
| 12616730 | Topical composition comprising an extract of combined herbs comprising longanae arillus for the treatment or alleviation of skin ulcer and the use thereof | 🖼🧊📄§ | 2026-05-05 | 2041-03-10 | 0 | 31 |
| 12616602 | Bacteria formulation and products including same | 🖼🧊📄§ | 2026-05-05 | 2041-08-04 | 0 | 31 |
| 12616702 | Use of reboxetine to treat narcolepsy | 🖼🧊📄§ | 2026-05-05 | 2044-08-29 | 0 | 31 |
| 12616673 | Compounds for use in the treatment of leukemia | 🖼🧊📄§ | 2026-05-05 | 2041-01-28 | 0 | 31 |
| 12616713 | Methods for enhancing vascular density | 🖼🧊📄§ | 2026-05-05 | 2043-01-20 | 0 | 31 |
| 12616703 | Methods of contraception using nomegestrol acetate and estradiol | 🖼🧊📄§ | 2026-05-05 | 2041-10-12 | 0 | 31 |
| 12616674 | Anti-fibrotic NEU3 inhibitor compounds and methods of use | 🖼🧊📄§ | 2026-05-05 | 2040-02-10 | 0 | 31 |
| 12616667 | Compositions and methods for improving neurological diseases and disorders | 🖼🧊📄§ | 2026-05-05 | 2042-11-14 | 0 | 31 |
| 12617782 | Pyridazinones as PARP7 inhibitors | 🖼🧊📄§ | 2026-05-05 | 2043-05-12 | 0 | 31 |
| 12616670 | N-phenyl-3-mercaptopropanamide derivatives as metallo-beta-lactamase inhibitors for the treatment of bacterial infections | 🖼🧊📄§ | 2026-05-05 | 2041-03-23 | 0 | 31 |
| 12618072 | Methods of treatment of SCN2A-related disorders | 🖼🧊📄§ | 2026-05-05 | 2044-09-13 | 0 | 31 |
| 12617825 | Methods and compositions for reducing the immunogenicity of chimeric notch receptors | 🖼🧊📄§ | 2026-05-05 | 2042-04-08 | 0 | 31 |
Page 1Next →